Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336803 · ClinicalTrials.gov registry record · Phase 2
Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
A Phase 2 study, sponsored by Heike E Daldrup-Link.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01336803 is a Phase 2 study that has completed, run by Heike E Daldrup-Link. The registered enrollment target is 32 participants.
The verdict
NCT01336803, a Phase 2 study, has completed, sponsored by Heike E Daldrup-Link.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correctly and may result in more timely treatment.
Interventions
- DRUG Feraheme
- PROCEDURE Magnetic Resonance Imaging (MRI) scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-08 |
| Est. Completion | 2023-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01336803
The ClinicalTrials.gov registry entry for NCT01336803 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heike E Daldrup-Link, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Feraheme is the first listed.
NCT01336803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01336803 about?
NCT01336803 is a clinical study titled "Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI". This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correct...
What is the current status of trial NCT01336803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2011-08. Estimated completion is 2023-10.
What interventions are being tested in trial NCT01336803?
The interventions under investigation include: Feraheme (DRUG), Magnetic Resonance Imaging (MRI) scan (PROCEDURE).
Who is sponsoring clinical trial NCT01336803?
This trial is sponsored by Heike E Daldrup-Link, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.